Recent trends in praziquantel nanoformulations for helminthiasis treatment

References

• de Moraes J, Geary TG. FDA-approved antiparasitic drugs in the 21st century: a success for helminthiasis? Trends Parasitol. 2020;36(7):573–575.
   PubMed Web of Science ®Google Scholar
• Lago EM, Xavier RP, Teixeira TR, et al. Antischistosomal agents: state of art and perspectives. Future Med Chem. 2018;10(1):89–120.
   PubMed Web of Science ®Google Scholar
• McManus DP, Dunne DW, Sacko M, et al. Schistosomiasis. Nat Rev Dis Primers. 2018;4(1):13.
   PubMed Web of Science ®Google Scholar
• You H, Harvie M, Du X, et al. Protective immune responses generated in a murine model following immunization with recombinant schistosoma japonicum insulin receptor. Int J Mol Sci. 2018;19(10):3088.
   Web of Science ®Google Scholar
• Colley DG, Bustinduy AL, Secor WE, et al. Human schistosomiasis. Lancet. 2014;383(9936):2253–2264.
   PubMed Web of Science ®Google Scholar
• Fürst T, Keiser J, Utzinger J. Global burden of human food-borne trematodiasis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(3):210–221.
   PubMed Web of Science ®Google Scholar
• Spangenberg T. Alternatives to praziquantel for the prevention and control of schistosomiasis. ACS Infect Dis. 2021;7:939–942.
   PubMed Web of Science ®Google Scholar
• Olliaro P, Delgado-Romero P, Keiser J. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother. 2014;69(4):863–870.
   PubMed Web of Science ®Google Scholar
• World Health Organization.Model list of essential medicines for children – 8th list, 2021.Geneva:World Health Organization;2021 . WHO/MHP/HPS/EML/2021.03). Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• The Pediatric Praziquantel Consortium. [ cited 01 mar 2022]. Available from: https://www.pediatricpraziquantelconsortium.org/
   Google Scholar
• de Lima LI, Py-Daniel KR, Guimarães MA, et al., Self-nanoemulsifying drug-. delivery systems improve oral absorption and antischistosomal activity of epiisopiloturine. Nanomedicine (Lond). 2018;13(7): 689–702.
   PubMed Web of Science ®Google Scholar
• Santos DS, Morais JAV, Vanderlei ÍAC, et al. Oral delivery of fish oil in oil-in-water nanoemulsion: development, colloidal stability and modulatory effect on in vivo inflammatory induction in mice. Biomed Pharmacother. 2021;133:110980.
   PubMed Web of Science ®Google Scholar
• de Araújo Silva DN, Silva NTD, Sena IAA, et al. Efficacy of antimicrobial photodynamic therapy with chloro-aluminum phthalocyanine on periodontal clinical parameters and salivary GSH and MDA levels in patients with periodontitis. Photodiagnosis Photodyn Ther. 2020;31:101843.
   PubMed Web of Science ®Google Scholar
• Silva LM, Marconato DG, Nascimento da Silva MP, et al. Licochalcone A-loaded solid lipid nanoparticles improve antischistosomal activity in vitro and in vivo. Nanomedicine (Lond). 2021;16(19):1641–1655.
   PubMed Web of Science ®Google Scholar
• Lago EM, Silva MP, Queiroz TG, et al. Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis. EBioMedicine. 2019;43:370–379.
   PubMed Web of Science ®Google Scholar
• de Brito MG, Mengarda AC, Oliveira GL, et al. Therapeutic effect of diminazene aceturate on parasitic blood fluke schistosoma mansoni infection. Antimicrob Agents Chemother. 2020;64(11):e01372–20.
   PubMed Web of Science ®Google Scholar
• Xavier RP, Mengarda AC, Silva MP, et al. H1-antihistamines as antischistosomal drugs: in vitro and in vivo studies. Parasit Vectors. 2020;13(1):278.
   PubMed Web of Science ®Google Scholar
• Crellen T, Walker M, Lamberton PH, et al. Reduced Efficacy of Praziquantel Against Schistosoma mansoni Is Associated With Multiple Rounds of Mass Drug Administration. Clin Infect Dis. 2016;63(9):1151–1159.
   PubMed Web of Science ®Google Scholar
• Zwang J, Olliaro P. Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. Parasit Vectors. 2017;10(1):47.
   PubMedGoogle Scholar
• Guerra RA, Silva MP, Silva TC, et al. In vitro and in vivo studies of spironolactone as an antischistosomal drug capable of clinical repurposing. Antimicrob Agents Chemother. 2019;63(3):e01722–18.
   PubMed Web of Science ®Google Scholar
• Mengarda AC, Silva MP, Cirino ME, et al. Licarin A, a neolignan isolated from nectandra oppositifolia nees & mart. (Lauraceae), exhibited moderate preclinical efficacy against schistosoma mansoni infection. Phytother Res. 2021;35(9):5154–5162.
   PubMed Web of Science ®Google Scholar
• Silva MP, Silva TM, Mengarda AC, et al. Brazilian red propolis exhibits antiparasitic properties in vitro and reduces worm burden and egg production in an mouse model harboring either early or chronic schistosoma mansoni infection. J Ethnopharmacol. 2021;264:113387.
   PubMed Web of Science ®Google Scholar
• Porto R, Mengarda AC, Cajas RA, et al. Antiparasitic properties of cardiovascular agents against human intravascular parasite schistosoma mansoni. Pharmaceuticals (Basel). 2021;14(7):686.
   PubMedGoogle Scholar
• Morais CS, Mengarda AC, Miguel FB, et al. Pyrazoline derivatives as promising novel antischistosomal agents. Sci Rep. 2021;11(1):23437.
   PubMed Web of Science ®Google Scholar
• Silva TC, Mengarda AC, Silva BC, et al. New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies. Future Med Chem. 2021;13(11):945–957.
   PubMed Web of Science ®Google Scholar
• Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58(2):265–278.
   PubMed Web of Science ®Google Scholar
• Cioli D, Pica-Mattoccia L. Praziquantel. Parasitol Res. 2003;90(S1):S3–S9.
   PubMedGoogle Scholar
• World Health Organization [Internet]. Summary of global update on implementation of preventive chemotherapy against NTDs in 2020; 2021 cited 2021 sep 24]. Available from: https://www.who.int/publications/i/item/who-wer9638-468-475
   Google Scholar
• Woelfle M, Seerden JP, de Gooijer J, et al. Resolution of praziquantel. PLoS Negl Trop Dis. 2011;5(9):e1260.
   PubMed Web of Science ®Google Scholar
• Wang WL, Song LJ, Chen X, et al. Synthesis and SAR studies of praziquantel derivatives with activity against Schistosoma japonicum. Molecules. 2013;18(8):9163–9178.
   PubMed Web of Science ®Google Scholar
• Meyer T, Sekljic H, Fuchs S, et al. Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Negl Trop Dis. 2009;3(1):e357.
   PubMed Web of Science ®Google Scholar
• Zdesenko G, Mutapi F. Drug metabolism and pharmacokinetics of praziquantel: a review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models. PLoS Negl Trop Dis. 2020;14(9):e0008649.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Sil PC. Role of nanostructures in improvising oral medicine. Toxicol Rep. 2019;6:358–368.
   PubMed Web of Science ®Google Scholar
• Adekiya TA, Kondiah PPD, Choonara YE, et al. A Review of nanotechnology for targeted anti-schistosomal therapy. Front Bioeng Biotechnol. 2020;8:32.
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124.
   PubMed Web of Science ®Google Scholar
• Aghebati-Maleki A, Dolati S, Ahmadi M, et al., Nanoparticles and cancer therapy: perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol. 2020;235(3): 1962–1972.
   PubMed Web of Science ®Google Scholar
• Zielińska A, Carreiró F, Oliveira AM, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731.
   PubMed Web of Science ®Google Scholar
• Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4(128):128ra39.
   PubMed Web of Science ®Google Scholar
• Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin Drug Deliv. 2015;12(9):1459–1473.
   PubMed Web of Science ®Google Scholar
• Albertini B, Perissutti B, Bertoni S, et al. Combining mechanochemistry and spray congealing for new praziquantel pediatric formulations in schistosomiasis treatment. Int J Mol Sci. 2019;20(5):1233.
   Web of Science ®Google Scholar
• Silva LD, Arrúa EC, Pereira DA, et al. Elucidating the influence of praziquantel nanosuspensions on the in vivo metabolism of Taenia crassiceps cysticerci. Acta Trop. 2016;161:100–105.
   PubMed Web of Science ®Google Scholar
• Torabi N, Dobakhti F, Faghihzadeh S, et al. In vitro and in vivo effects of chitosan-praziquantel and chitosan-albendazole nanoparticles on Echinococcus granulosus metacestodes. Parasitol Res. 2018;117(7):2015–2023.
   PubMed Web of Science ®Google Scholar
• Sadek G, Harba N, Elrefai S, et al. Efficacy of praziquantel loaded chitosan nanoparticles against both adult and schistosomula stages of schistosoma mansoni. J Egypt Soc Parasitol. 2018;48(3):629–638.
   Google Scholar
• Doktorovová S, Kovačević AB, Garcia ML, et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2016;108:235–252.
   PubMed Web of Science ®Google Scholar
• Tao J, Chow SF, Zheng Y. Application of flash nanoprecipitation to fabricate poorly water-soluble drug nanoparticles. Acta Pharm Sin B. 2019;9(1):14–18.
   Web of Science ®Google Scholar
• de Souza AL, Andreani T, de Oliveira RN, et al. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. Int J Pharm. 2014;463(1):31–37.
   PubMedGoogle Scholar
• Kolenyak-Santos F, Garnero C, de Oliveira RN, et al. Nanostructured lipid carriers as a strategy to improve the In vitro Schistosomiasis activity of praziquantel. J Nanosci Nanotechnol. 2015;15(1):761–772.
   PubMed Web of Science ®Google Scholar
• Radwan A, El-Lakkany NM, William S, et al. A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection. Parasit Vectors. 2019;12(1):304.
   PubMedGoogle Scholar
• Andrade LN, Marques C, Barbosa T, et al. Praziquantel-loaded solid lipid nanoparticles: production, physicochemical characterization, release profile, cytotoxicity and in vitro activity against schistosoma mansoni. J Drug Deliv Sci Technol. 2020;58:101784.
   Web of Science ®Google Scholar
• Xu J, Tao J, Wang J. Design and application in delivery system of intranasal antidepressants. Front Bioeng Biotechnol. 2020;8:626882.
   PubMed Web of Science ®Google Scholar
• Zhang L, Han C, Liu M, et al. The formation, stability of DHA/EPA nanoemulsion prepared by emulsion phase inversion method and its application in apple juice. Food Res Int. 2020;133:109132.
   PubMed Web of Science ®Google Scholar
• Håkansson A. Emulsion formation by homogenization: current understanding and future perspectives. Annu Rev Food Sci Technol. 2019;10(1):239–258.
   PubMedGoogle Scholar
• Ganesan P, Karthivashan G, Park SY, et al. Microfluidization trends in the development of nanodelivery systems and applications in chronic disease treatments. Int J Nanomedicine. 2018;13:6109–6121.
   PubMed Web of Science ®Google Scholar
• Amara RO, Ramadan AA, El-Moslemany RM, et al. Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential schistosoma mansoni tegumental targeting. Int J Nanomedicine. 2018;13:4493–4505.
   PubMed Web of Science ®Google Scholar
• Zoghroban HS, El-Kowrany SI, Aboul Asaad IA, et al. Niosomes for enhanced activity of praziquantel against schistosoma mansoni: in vivo and in vitro evaluation. Parasitol Res. 2019;118(1):219–234.
   PubMed Web of Science ®Google Scholar
• Eissa MM, El-Azzouni MZ, El-Khordagui LK, et al. Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni. Parasit Vectors. 2020;13(1):474.
   PubMed Web of Science ®Google Scholar
• Eissa MM, El-Azzouni MZ, El-Khordagui LK, et al. Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni. Acta Trop. 2020;212:105714.
   PubMed Web of Science ®Google Scholar
• Liu G, Hou S, Tong P, et al. Liposomes: preparation, characteristics, and application strategies in analytical chemistry. Crit Rev Anal Chem. 2022;52(2):392–412.
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen D, Pan Y, et al. Nanoparticles for antiparasitic drug delivery. Drug Deliv. 2019;26(1):1206–1221.
   PubMed Web of Science ®Google Scholar
• Hrckova G, Velebny S. Effects of free and liposomized praziquantel on worm burden and antibody response in mice infected with Mesocestoides corti tetrathyridia. J Helminthol. 1995;69(3):213–221.
   PubMed Web of Science ®Google Scholar
• Mourão SC, Costa PI, Salgado HR, et al. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int J Pharm. 2005;295(1–2):157–162.
   PubMedGoogle Scholar
• Frezza TF, Gremião MPD, Zanotti-Magalhães EM, et al. Liposomal-praziquantel: efficacy against schistosoma mansoni in a preclinical assay. Acta Trop. 2013;128(1):70–75.
   PubMed Web of Science ®Google Scholar
• Labib El Gendy AEM, Mohammed FA, Abdel-Rahman SA, et al. Effect of nanoparticles on the therapeutic efficacy of praziquantel against Schistosoma mansoni infection in murine models. J Parasit Dis. 2019;43(3):416–425.
   PubMedGoogle Scholar
• Hayashi K, Sato Y, Maruoka H, et al. Organic–inorganic hybrid nanoparticles for tracking the same cells seamlessly at the cellular, tissue, and whole body levels. ACS Biomater Sci Eng. 2017;3(6):1129–1135.
   PubMed Web of Science ®Google Scholar
• Dhaval M, Makwana J, Sakariya E, et al. Drug nanocrystals: a comprehensive review with current regulatory guidelines. Curr Drug Deliv. 2020;17(6):470–482.
   PubMed Web of Science ®Google Scholar
• Mousa M, Evans ND, Oreffo ROC, et al. Clay nanoparticles for regenerative medicine and biomaterial design: a review of clay bioactivity. Biomaterials. 2018;159:204–214.
   PubMed Web of Science ®Google Scholar
• Borrego-Sánchez A, Carazo E, Albertini B, et al. Conformational polymorphic changes in the crystal structure of the chiral antiparasitic drug praziquantel and interactions with calcium carbonate. Eur J Pharm Biopharm. 2018;132:180–191.
   PubMed Web of Science ®Google Scholar
• Borrego-Sánchez A, Sánchez-Espejo R, Albertini B, et al. Ground calcium carbonate as a low cost and biosafety excipient for solubility and dissolution improvement of praziquantel. Pharmaceutics. 2019;11(10):533.
   Web of Science ®Google Scholar
• Dardir FM, Mohamed AS, Abukhadra MR, et al. Cosmetic and pharmaceutical qualifications of egyptian bentonite and its suitability as drug carrier for praziquantel drug. Eur J Pharm Sci. 2018;115:320–329.
   PubMed Web of Science ®Google Scholar
• Dong J, Cheng Z, Tan S, et al. Clay nanoparticles as pharmaceutical carriers in drug delivery systems. Expert Opin Drug Deliv. 2021;18(6):695–714.
   PubMed Web of Science ®Google Scholar
• El-Feky GS, Mohamed WS, Nasr HE, et al. Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine schistosoma mansoni infection. Antimicrob Agents Chemother. 2015;59(6):3501–3508.
   PubMed Web of Science ®Google Scholar
• Tawfeek GM, Baki MHA, Ibrahim AN, et al. Enhancement of the therapeutic efficacy of praziquantel in murine Schistosomiasis mansoni using silica nanocarrier. Parasitol Res. 2019;118(12):3519–3533.
   PubMed Web of Science ®Google Scholar
• Pardhi VP, Verma T, Flora SJS, et al. Nanocrystals: an overview of fabrication, characterization and therapeutic applications in drug delivery. Curr Pharm Des. 2018;24(43):5129–5146.
   PubMed Web of Science ®Google Scholar
• Sun L, Hu Y, Zhang L. Recent trends in nanocrystals for pharmaceutical applications. Curr Pharm Des. 2018;24(21):2394–2402.
   PubMed Web of Science ®Google Scholar
• Zanolla D, Perissutti B, Passerini N, et al. A new soluble and bioactive polymorph of praziquantel. Eur J Pharm Biopharm. 2018;127:19–28.
   PubMed Web of Science ®Google Scholar
• Lombardo FC, Perissutti B, Keiser J. Activity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model. Eur J Pharm Biopharm. 2019;142:240–246.
   PubMed Web of Science ®Google Scholar
• Espinosa-Lara JC, Guzman-Villanueva D, Arenas-García JI, et al. Cocrystals of active pharmaceutical ingredients praziquantel in combination with oxalic, malonic, succinic, maleic, fumaric, glutaric, adipic, and pimelic acids. Cryst Growth Des. 2013;13:169–185.
   Web of Science ®Google Scholar
• Gigliobianco MR, Casadidio C, Censi R, et al. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics. 2018;10(3):134.
   PubMed Web of Science ®Google Scholar